gliclazide has been researched along with endothelin-1 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, L; Renier, G | 1 |
Edwards, TM; Verwey, LJ | 1 |
2 other study(ies) available for gliclazide and endothelin-1
Article | Year |
---|---|
The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells.
Topics: Administration, Oral; Antioxidants; Aorta; Apoptosis; Caspase 3; Caspase 9; Caspase Inhibitors; Cells, Cultured; Cysteine Proteinase Inhibitors; Endothelial Cells; Endothelin-1; Gliclazide; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Matrix Metalloproteinase 9; NF-kappa B; Oxidative Stress; Proto-Oncogene Proteins c-akt; Scavenger Receptors, Class E | 2009 |
Gap junctions and memory: an investigation using a single trial discrimination avoidance task for the neonate chick.
Topics: Animals; Astrocytes; Avoidance Learning; Central Nervous System Agents; Chickens; Dose-Response Relationship, Drug; Endothelin-1; Gap Junctions; Glycyrrhetinic Acid; Memory; Memory, Short-Term; Neuropsychological Tests; Random Allocation; Time Factors; Tolbutamide | 2010 |